Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
10 Giugno 2024 - 1:30PM
Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company
focused on developing next generation therapeutics to target
difficult-to-treat cancers, today announced the appointment of
Michael A. Metzger to its Board of Directors, effective June 10,
2024. Mr. Metzger has over 25 years of experience in the
biopharmaceutical sector, currently serving as Chief Executive
Officer and as a member of the Board of Directors of Syndax
Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.
“We are delighted to have Michael, a proven leader in our
industry with a robust track record of success, join the board,”
said Lara S. Sullivan, M.D., President and Chief Executive Officer
of Pyxis Oncology. “As Pyxis Oncology continues to grow, empowered
by our novel approach to developing antibody-drug conjugates
(ADCs), Michael’s deep knowledge of the biopharmaceutical landscape
and experience building companies that drive innovation will be
invaluable.”
“Pyxis Oncology’s novel ADC approach and impressive pipeline
comprised of next-generation therapeutics are aimed to target
difficult-to-treat cancers and improve the quality of life of
patients,” said Mr. Metzger. “I look forward to working with the
deeply experienced board and leadership team assembled at Pyxis
Oncology to further advance the Company’s mission of improving
outcomes for patients with cancer.”
Before joining Syndax, Mr. Metzger served in multiple senior
leadership roles within the biopharmaceutical industry including
CEO of Regado Biosciences leading to its merger with Tobira
Therapeutics and sale to Allergan, COO of Mersana Therapeutics and
senior business development roles at Forest Laboratories. Michael
most recently served on the board of CTI Biopharma Corp., a
publicly traded biopharmaceutical company which was acquired by
SOBI AB in 2023. Mr. Metzger received a B.A. from George Washington
University and an M.B.A. in finance from the New York University
Stern School of Business.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on
defeating difficult-to-treat cancers. The company is efficiently
building next generation therapeutics that hold the potential for
mono and combination therapies. PYX-201, an antibody-drug conjugate
(ADC) that uniquely targets EDB+FN within the tumor stroma, and
PYX-106, a fully human Siglec-15-targeting antibody designed to
block suppression of T-cell proliferation and function, are being
evaluated in ongoing Phase 1 clinical studies in multiple types of
solid tumors. Pyxis Oncology’s therapeutic candidates are designed
to directly kill tumor cells and to address the underlying
pathologies created by cancer that enable its uncontrollable
proliferation and immune evasion. Pyxis Oncology’s ADC and
immuno-oncology (IO) programs employ novel and emerging strategies
to target a broad range of solid tumors resistant to current
standards of care. To learn more,
visit www.pyxisoncology.com or follow us
on Twitter and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
These statements are often identified by the use of words such as
“on track,” “anticipate,” “believe,” “can,” “continue,” “could,”
“estimate,” “expect,” “intend,” “likely,” “may,” “might,”
“objective,” “ongoing,” “plan,” “potential,” “predict,” “project,”
“should,” “to be,” “will,” “would,” or the negative or plural of
these words, or similar expressions or variations, although not all
forward-looking statements contain these words. We cannot assure
you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual
results could differ materially from those expressed or implied by
these forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to,
those identified herein, and those discussed in the section titled
“Risk Factors” set forth in the Company’s Annual Report on Form
10-K filed for the year ended December 31, 2023 with SEC on March
21, 2024, the Company’s Quarterly Report on Form 10-Q for the
quarter ended March 31, 2024 and our other filings, each of which
is on file with the Securities and Exchange Commission. These risks
are not exhaustive. New risk factors emerge from time to time, and
it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. In addition, statements that “we
believe” and similar statements reflect our beliefs and opinions on
the relevant subject. These statements are based upon information
available to us as of the date hereof and while we believe such
information forms a reasonable basis for such statements, such
information may be limited or incomplete, and our statements should
not be read to indicate that we have conducted an exhaustive
inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain, and
investors are cautioned not to unduly rely upon these statements.
Except as required by law, we undertake no obligation to update any
forward-looking statements to reflect events or circumstances after
the date of such statements.
Pyxis Oncology Contact Pamela
Connealy CFO and COO ir@pyxisoncology.com
Grafico Azioni Pyxis Oncology (NASDAQ:PYXS)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Pyxis Oncology (NASDAQ:PYXS)
Storico
Da Dic 2023 a Dic 2024